The survival, even after aggressive multimodality treatment, remains poor.4 Therefore new subgroups that might benefit from new treatments are being identified.5,6 In the last few years, much effort and research in lung cancer has been oriented to molecular targets, e.g. EGFR activating mutations. The gene discussed is EGFR; the disease is lung carcinoma.